Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SUNRISE: A Phase II Randomized Control Study of Sintilimab Combined With Anlotinib Versus Standard Platinum-based Chemotherapy as a First-line Treatment in Patients With Advanced NSCLC

NCT04124731 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT04124731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04124731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SUNRISE: A Phase II Randomized Control Study of Sintilimab Combined With Anlotinib Versus Standard Platinum-based Chemotherapy as a First-line Treatment in Patients With Advanced NSCLC
Lead sponsor
Shanghai Chest Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2019
Completion date
April 30, 2022
Enrollment
98 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung cancer